HotSpot Therapeutics, Inc. v. Nurix Therapeutics, Inc.

Opinion

3 4 HOTSPOT THERAPEUTICS, INC., Case No. 22-cv-04109-TSH 5 Plaintiff, 6 y. ORDER TO SHOW CAUSE 8 Defendant. 9 10 Plaintiff/Counterclaim Defendant HotSpot Therapeutics, Inc. moves for partial summary 11 || judgment in its favor that Defendant/Counterclaim Plaintiff Nurix Therapeutics, Inc.’s trade secret (12 misappropriation claims are barred by the applicable three-year statute of limitations. ECF No. 5 13 189. Nurix failed to file an opposition in compliance with Civil Local Rule 7. The Court 14 || possesses the inherent power to dismiss an action sua sponte “to achieve the orderly and 3 15. || expeditious disposition of cases.” Link v. Wabash R.R. Co., 370 U.S. 626, 629-33 (1962). 16 Accordingly, the Court hereby VACATES the March 14, 2024 noticed hearing date and 5 7 ORDERS Nurix to show cause why its claims should not be dismissed for failure to prosecute and 5 18 failure to comply with court deadlines. Nurix shall file a declaration by February 29, 2024 and 19 simultaneously file either an opposition in compliance with Civil Local Rule 7-3(a) or a statement of nonopposition in compliance with Local Rule 7-3(b). If Nurix file an opposition, HotSpot may > file any reply by March 8, 2024.

Notice is hereby provided that failure to file a written response will be deemed an

admission that you do not intend to prosecute, and your claims will likely be dismissed. Thus, it is

imperative the Court receive a written response by the deadline above.

IT IS SO ORDERED.

26 Dated: February 21, 2024 □ 27 THOMAS S. HIXSON □ 28 United States Magistrate Judge